Showing 4051-4060 of 9807 results for "".
- Fractional HiFR Helps Fight Signs of Aging on Lower Face/Neckhttps://practicaldermatology.com/news/fractional-hifr-helps-fight-signs-of-aging-on-lower-faceneck/2458469/Fractional high intensity focused radiofrequency (HiFR) is safe and effective in the treatment of mild to moderate laxity of the lower face and neck, new research suggests. The study was selected as Editor’s Choice in the July 2016 issue of
- MRF to UPSTF: Reconsider Supporting Annual Skin Cancer Checkshttps://practicaldermatology.com/news/mrf-to-upstf-reconsider-support-for-annual-skin-cancer-checks/2458479/The Melanoma Research Foundation (MRF) is urging the U.S. Preventive Services Task Force’s (USPSTF) to reconsider their recent announcement stating that insufficient data exists to support a recommendation for annual skin canc
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new
- Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Submental Fullnesshttps://practicaldermatology.com/news/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-submental-fullness/2458511/The Swedish Medical Products Agency (MPA) gave its thumbs up to Allergan’s BELKYRA® (deoxycholic acid). BELKYRA® is being
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the
- ASA Lauds Three Honorees at Spring Galahttps://practicaldermatology.com/news/asa-lauds-three-honorees-at-spring-gala/2458602/The American Skin Association (ASA) honored Yale Educator Irwin M. Braverman, MD, Melanoma Researcher John M. Kirkwood MD and Nestlé’s SHIELD program at their Spring gala in New
- APP® Membership Now Has More Rewards: Three Syneron Candela Platformshttps://practicaldermatology.com/news/app-membership-now-has-more-rewards-three-syneron-candela-platforms/2458655/Syneron Medical Ltd. and Allergan plc are joining forces to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan Partner Privileges® (APP®</
- Dermwire's Inside Scoop on Hottest Expected AAD2016 Launcheshttps://practicaldermatology.com/news/dermwires-inside-scoop-on-hottest-expected-aad2016-launches/2458670/The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest – and hopefully greatest --- innovations or iterations in skin care products and technologies. And the
- SENTÉ Raises $5 million, Appoints New CEOhttps://practicaldermatology.com/news/sent-raises-5-million-appoints-new-ceo/2458713/There’s big news coming out of SENTÉ this week. Fresh of the announcement that they closed on a $5 million financing round, the company also appointed Laurent Combredet as President and Chief Executive Officer. Mr. Combredet was G